Medipharm launches Shake & Puff inhaler in Canada

Executive Summary

• Medipharm Labs Corp. has launched a new nighttime inhaler in Canada, expanding its cannabinol (CBN) oil portfolio with a new metered dose inhaler containing CBN and THC.
• The product is designed for smoke-free, precise dosing with rapid onset, targeting both adult-use consumers in Ontario and medical patients via the Canna Farms platform.
• The launch supports the company's broader strategy to scale precision cannabinoid delivery methods globally, with future plans to expand the inhaler line to include cannabidiol (CBD) and cannabigerol (CBG) options.

Key Details

• Product Name: Shake & Puff cannabinol tetrahydrocannabinol (THC) nighttime inhaler.
• Formulation: Metered dose inhaler delivering a precise formulation of minor cannabinoid CBN and THC.
• Delivery Mechanism: Smoke-free and vapour-free direct-to-lung delivery, offering rapid onset and higher bioavailability compared to ingested formats.
• User Experience: Designed for discretion, portability, and ease of use (similar to asthma inhalers) with no lingering smell or byproducts.
• Availability:
  • Available through select Ontario adult-use retailers.
  • Available nationally through the Canna Farms medical platform.
  • Expansion to additional provinces and sales channels is planned.
• Future Roadmap: The company plans to expand the inhaler offering with additional cannabidiol (CBD) and cannabigerol (CBG) options in the future.
• Strategic Context: The launch builds on the success of the company's THC inhaler introduced earlier in the year and reinforces Medipharm's position in pharma-grade cannabinoid innovation.

Notable Quotes

• "The launch of our CBN THC metered dose inhaler represents a significant step forward in our strategy to deliver innovative, pharma-grade cannabinoid products globally. As international markets increasingly seek smoke-free, precisely dosed formats, Medipharm is well positioned to lead with differentiated solutions that reflect both consumer wellness trends and medical needs. This product not only strengthens our Canadian portfolio but also supports our broader vision to scale precision cannabinoid delivery methods across regulated cannabis markets worldwide." — David Pidduck, Chief Executive Officer